Extrawell Pharmaceutical Holdings (HKSE:00858) Revenue : HK$68.62 Mil (TTM As of Sep. 2023)

View and export this data going back to 1999. Start your Free Trial

What is Extrawell Pharmaceutical Holdings Revenue?

Extrawell Pharmaceutical Holdings's revenue for the six months ended in Sep. 2023 was HK$30.14 Mil. Its revenue for the trailing twelve months (TTM) ended in Sep. 2023 was HK$68.62 Mil. Extrawell Pharmaceutical Holdings's Revenue per Share for the six months ended in Sep. 2023 was HK$0.01. Its Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2023 was HK$0.03.

Warning Sign:

Extrawell Pharmaceutical Holdings Ltd revenue per share has been in decline for the last 5 years.

During the past 12 months, the average Revenue per Share Growth Rate of Extrawell Pharmaceutical Holdings was 31.60% per year. During the past 3 years, the average Revenue per Share Growth Rate was -2.90% per year. During the past 5 years, the average Revenue per Share Growth Rate was -3.20% per year. During the past 10 years, the average Revenue per Share Growth Rate was -10.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

During the past 13 years, Extrawell Pharmaceutical Holdings's highest 3-Year average Revenue per Share Growth Rate was 12.30% per year. The lowest was -21.60% per year. And the median was -7.20% per year.

Extrawell Pharmaceutical Holdings Revenue Historical Data

The historical data trend for Extrawell Pharmaceutical Holdings's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Extrawell Pharmaceutical Holdings Revenue Chart

Extrawell Pharmaceutical Holdings Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Revenue

Get a 7-Day Free Trial

89.22

77.58

78.80

73.93

72.58

Extrawell Pharmaceutical Holdings Semi-Annual Data
	Mar14	Sep14	Mar15	Sep15	Mar16	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
Revenue	Get a 7-Day Free Trial															43.46	30.46	34.10	38.48	30.14

Competitive Comparison of Extrawell Pharmaceutical Holdings's Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Extrawell Pharmaceutical Holdings's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Extrawell Pharmaceutical Holdings's Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Extrawell Pharmaceutical Holdings's Revenue distribution charts can be found below:

* The bar in red indicates where Extrawell Pharmaceutical Holdings's Revenue falls into.

Extrawell Pharmaceutical Holdings Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Sep. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$68.62 Mil.

Extrawell Pharmaceutical Holdings (HKSE:00858) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:

Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.

Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.

Extrawell Pharmaceutical Holdings Revenue Related Terms

Thank you for viewing the detailed overview of Extrawell Pharmaceutical Holdings's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Extrawell Pharmaceutical Holdings (HKSE:00858) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Extrawell Pharmaceutical Holdings Ltd (HKSE:00858) » Definitions » Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

979 King’s Road, Suites 2206-08, 22nd Floor, Devon House, Taikoo Place, Quarry Bay, Hong Kong, HKG

Website

http://www.extrawell.com.hk

Extrawell Pharmaceutical Holdings Ltd is an investment holding company. The company's operating segment includes Manufacturing; Trading and Gene Development. It generates maximum revenue from the Manufacturing segment. The manufacturing segment is engaged in the development, manufacture, and sales of pharmaceutical products. Its trading segment is engaged in the marketing and distribution of imported pharmaceutical products. The gene development segment is engaged in the commercial exploitation and development of genome-related technology. Geographically, it derives a majority of its revenue from China.

Executives

Mao Yumin	2201 Interest of corporation controlled by you
Biowindow Gene Development (hong Kong) Limited	2201 Interest of corporation controlled by you
Ease Gold Investments Limited	2201 Interest of corporation controlled by you
Jnj Investments Ltd	2201 Interest of corporation controlled by you
United Gene Group Ltd	2201 Interest of corporation controlled by you
United Gene Holdings Limited	2201 Interest of corporation controlled by you
United Gene International Holdings Group Limited	2101 Beneficial owner
Xie Yi	2201 Interest of corporation controlled by you
Huang Zhenping	2101 Beneficial owner
United Gene Industry Group Limited	2101 Beneficial owner
Chen Xuhua	2202 Interest of your spouse
Cheng Yong	2201 Interest of corporation controlled by you

Extrawell Pharmaceutical Holdings (HKSE:00858) Headlines

No Headlines